karyotic phylogenetic spectrum. The ciliary axoneme is a complex molecular motor that effects motility through the interaction of axonemal dyneins in concert with axonemal microtubules and other structural accessory elements (14, 24, 32, 34) . Dyneins imaged by electron microscopy appear as longitudinal arrays of appendages (arms) positioned at discrete intervals along the A subfiber of each of the nine peripheral microtubular pairs of the axoneme (5, 16) . In ultrathin section views, inner and outer dynein arms appear as projections from the A subfiber of each microtubular doublet, with the outer arm often exhibiting a prominent "hook."
Each dynein arm is a very large multimeric microtubule-activated ATPase that generates interdoublet forces responsible for ciliary motility. The inner and outer arms are distinct dynein isoforms based upon differences in their structures (reviewed in Ref. 32) , biochemical compositions (30, 31, 40) , and functions (reviewed in Refs. 3 and 17) . In addition to the axonemal dyneins, there are cytoplasmic dyneins that are involved in essential functions of the cell cytoskeleton, including retrograde intracellular transport, mitosis, and maintenance of the Golgi apparatus (reviewed in Ref. 19) .
Each functional dynein motor complex is composed of a unique combination of heavy, intermediate, and light chains (reviewed in Ref. 20) . The dynein heavy chains (DHCs) are a family of very large (Ͼ500 kDa) polypeptides that bear ATPase and microtubule-binding domains. Organisms that employ cilia, flagella, or both express a multitude of DHC isoforms (1, 12, 18, 28, 34, 35, 37, 39) . For example, the biflagellate green alga Chlamydomonas is known to express at least 16 DHCs (33) . Phylogenetic analyses of partial predicted amino acid sequences of putative DHCs suggest that a given DHC is more closely related to the homologous chain in other species than it is to the other DHCs of the same species (13, 34) . This observation reinforces the notion that each functional dynein is defined by its DHCs, whose sequences and functions were highly conserved as species evolved.
The high degree of DHC sequence conservation has led to the identification of a number of putative human DHC genes (6, 7, 22, 23, 28, 29, 36, 38, 39) . One of these, DNEL1, has been shown to have a protein product that is a component of cilia and that has biochemical properties characteristic of a DHC (36) . Moreover, the expression of DNEL1 mRNA has been temporally associated with airway epithelial ciliogenesis in vitro (36) . Determination of the complete predicted amino acid sequence of the DNEL1 gene product as it is expressed in airway epithelium (W. Reed, unpublished observations) has revealed that it is derived from a putative human DHC gene identified previously on the basis of partial cDNA sequences (GenBank Accession numbers U61740 and AJ132088). This gene is the human homolog of rat dynein-like protein 9 (37) . It has been given the gene symbol DNAH9. Taken together, the data strongly support the notion that DNAH9/ DNEL1 is an axonemal DHC gene whose expression in airway epithelium is restricted to ciliated cells.
In this study, we have examined DNAH9 expression in the large conducting airways during human fetal development by light and electron microscopic immunocytochemistry and quantitative RT-PCR analyses. This study has provided some new insights into temporal aspects of early gene expression as it relates to ciliogenesis in the developing and mature human airways.
MATERIALS AND METHODS
Tissue acquisition procedures. Human fetal trachea and lung were obtained at the time of therapeutic abortion through a tissue procurement agency (Anatomic Gift Foundation, Woodbine, GA). The gestational ages of the specimens ranged from ϳ8 to 22 wk. The entire extrathoracic trachea from each of two to three specimens from each gestational interval was separated from the remainder of the lung. Because of the small organ size and acquisition procedures, it was not possible to further dissect the intrathoracic trachea or other regions of the parenchymal lung more completely. Normal tracheobronchial epithelium was obtained from healthy, nonsmoking adult male volunteers participating in inhalation toxicology studies in the Environmental Protection Agency Human Studies Facility at the University of North Carolina at Chapel Hill. Epithelium was obtained by forceps biopsy at the time of bronchoscopy. All procedures involving human subjects were approved by an institutional review board, and all volunteers gave informed consent before their participation.
Real-time RT-PCR. Extraction of total RNA and first-strand cDNA synthesis was performed as described previously (9) . Relative amounts of mRNAs encoding glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and human ciliary DNAH9 in total RNAs were estimated by quantitative fluorogenic amplification of first-strand cDNAs using a Prism 7700 Sequence Detection System (Applied Biosystems, Foster City, CA), TaqMan Universal PCR Master Mix (Applied Biosystems), and the primers and fluorophore-labeled probes described at the end of this section. Relative amounts of 18S ribosomal RNA were estimated using TaqMan ribosomal RNA control reagents (Applied Biosystems). Each estimate was performed in a separate amplification using a 2.5-l aliquot of first-strand cDNAs as template. Real-time fluorescence measurements were used to determine the threshold cycle for each amplification. Serial dilutions of recombinant plasmids bearing the complete coding region of human GAPDH, a fragment of human 18S rRNA, or a fragment of the human DNAH9 cDNA were amplified in parallel reactions and used to construct GAPDH, 18S rRNA, and DNAH9 standard curves relating the threshold cycle to molecules of plasmid standard. The standard curves were used to estimate the relative amounts of GAPDH, 18S rRNA, and DNAH9 cDNAs in each sample relative to their respective standards. The relative amount of DNAH9 cDNA in each sample was normalized to the relative amount of 18S rRNA or GAPDH cDNA, yielding an index proportional to the relative abundance of DNAH9 mRNA in each sample. Primers and fluorophore-labeled probes for GAPDH and DNAH9 were designed using either Primer Express software (Applied Biosystems) or Primer Designer software (Scientific and Educational Software, Durham, NC). Probes were labeled at the 5Ј end with either 6-carboxyfluorescein (FAM) or 6-carboxy-4Ј,5Ј-dichloro-2Ј,7-dimethoxyfluorescein (JOE) and at the 3Ј end with 6-carboxytetramethylrhodamine (TAMRA). Primer and probe sequences were as follows: GAPDH, probe: 5Ј-JOE-CAAGCTTCCCGTTCTCAGCC-TAMRA-3Ј, sense: 5Ј-GAAGGTGAAGGTCGGAGTC-3Ј, and antisense: 5Ј-GAA-GATGGTGATGGGATTTC-3Ј; DNAH9, probe: 5Ј-FAM-TC-TTCAGAAGACCCTCCACCACGTG-TAMRA-3Ј; sense: 5Ј-GAGAACCAGGAAGTCAAGGAATG-3Ј, and antisense: 5Ј-GCTGGACCTGCTGACTCAGA-3Ј.
Immunoblotting. A fragment of a putative human axonemal outer arm DHC cDNA subsequently identified as DNAH9 was cloned by long-range PCR from a human tracheal cDNA library. A monoclonal antibody identified as PQD-189 was raised against a 124-amino acid region of DNAH9. The cloning procedures and subsequent generation and characterization of the monoclonal antibody have been detailed elsewhere (36) . The specificity of the antibody was investigated by immunoblotting of ciliary axonemal proteins as follows. Axonemes were isolated as described (36) from in vitro differentiated human airway epithelial cultures. The axonemes were suspended in V1 photolysis buffer containing 30 mM HEPES, pH 7.4, 5 mM Mg 2SO4, 1 mM EGTA, 0.1 mM EDTA, 50 mM NaCl, 140 mM ␤-mercaptoethanol, 1 mM dithiothreitol, 500 M ATP, 100 M NaVO3, and 1ϫ protease inhibitor cocktail set III (Calbiochem, San Diego, CA). Onehalf of the axoneme suspension was held on ice, whereas the other one-half was irradiated on ice for 10 min with 254-nm ultraviolet light in a Stratalinker (Stratagene, San Diego, CA). Samples were dissolved in NuPAGE sample buffer and separated in 3-8% NuPAGE Tris-acetate gels according to the supplier's instructions (Invitrogen, San Diego, CA). For gels that were immunoblotted, each lane was loaded with a volume of axonemes in NuPAGE sample buffer estimated to be derived from approximately three well-ciliated 12-mmdiameter cultures (ca. 15 g protein). Each lane of gels that were silver stained was loaded with approximately one-tenth of the volume loaded on immunoblotted gels (ca. 1.5 g protein). Electrophoresis was carried out for 6 h to enhance the separation of DHCs. Gels were stained with a Silver-Xpress silver staining kit according to the supplier's instructions (Invitrogen) or blotted on nitrocellulose as described previously (36) . Blots were probed with a 1:50 dilution of a 50ϫ concentrate of PQD-189 hybridoma supernatant and developed with a 1:5,000 dilution of horseradish peroxidaseconjugated donkey anti-mouse IgG (Jackson Immunoresearch Laboratories, West Grove, PA) and Super Signal West Pico chemiluminescence reagents (Pierce, Rockford, IL).
Chemiluminescence was recorded using a Genegnome chemiluminescence imager (Syngene, Frederick, MD).
In situ hybridization histochemistry. One microgram of linear plasmid DNA (pBluescript SKϩ, Stratagene, La Jolla, CA) containing 346 bases of the human axonemal dynein coding region was used as a template for generating riboprobes. T7 RNA polymerase (1 U/l; Boehringer Mannheim) and 1ϫ Digoxigenin-RNA labeling mix (Boehringer Mannheim) were incubated in polymerase buffer (40 mM Tris, pH 7.9 at 37°C, 6 mM magnesium chloride, and 2 mM spermidine) for 2 h at 37°C, and DNA was then degraded with RQ1 (RNAse-free DNase; Promega, Madison, WI). The probe was Fig. 1 . Specificity and sensitivity of the dynein heavy chain 9 (DNAH9) mRNA TaqMan assay. DNAH9 and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) cDNA levels in cDNA templates were determined by real-time PCR using TaqMan assays. A and B: amplification plots relating normalized fluorescence above baseline (⌬Rn) to cycle number are shown for amplifications of DNAH9 (A) or GAPDH (B) cDNA from reverse-transcribed total RNAs isolated from primary human airway epithelial cell cultures in various stages of mucociliary differentiation. The stages of differentiation were day 0 (0), before initiation of mucociliary differentiation (nonciliated), and days 4 (4; nonciliated) and 12 (12; ca. 20% ciliated cells) after induction of differentiation. Background levels for the assay were determined by the signal from amplification with no added template (NT). C: histogram of reproducibility of data in A. Means Ϯ SE (n ϭ 5) of DNAH9 mRNA molecules detected in cultures from 5 different donors on days 0 (undifferentiated; ND, not detected), 4, 8, and 12. D and E: amplification plots of triplicate determinations of DNAH9 cDNA levels in templates from 9-wk trachea (D) and lung (E) in relation to amplification plots for the 450 molecule DNAH9 cDNA standard (450°C) and the no template control (NT). The signal from the no template control is shown in E but was off scale (low) in D (arrow). In the amplification plots the horizontal line shows the threshold ⌬Rn used to compute the threshold cycle for each amplification. Fig. 2 . Kinetics of DNAH9 mRNA expression in developing human trachea and lung. DNAH9, 18S rRNA, and GAPDH cDNA levels in cDNA templates were determined by real-time PCR using TaqMan assays. A-D: amplification plots of single determinations of DNAH9 (A and C) and 18S rRNA (B and D) cDNA levels in reverse-transcribed total RNA from 9-, 13-, 15-, and 18-wk trachea (A and B) and lung (C and D). The signal from the no template control is shown in C but was off scale (low) in A, B, and D (arrow). The horizontal line in each plot shows the threshold ⌬Rn used to compute the threshold cycle for each amplification. E and F: relative abundance of DNAH9 mRNA with respect to 18S rRNA (E) and GAPDH (F) mRNA at various gestational ages of trachea (s) and lung (OE). Two to five determinations of DNAH9 mRNA, GAPDH mRNA, and 18S rRNA levels were done for each template. Mean Ϯ SE of the relative abundance of DNAH9 is shown. precipitated, air-dried, and resuspended in sterile water. Labeling efficiency was determined by comparison with a digoxigenin-labeled standard (Boehringer Mannheim).
In situ hybridization histochemistry to localize transcripts was performed as previously described (25) with some modifications. Tissue sections were dewaxed in a 3:1 mixture of Hemo-De (Fisher Scientific, Pittsburgh, PA) and xylenes, hydrated in decreasing ethanol concentrations to distilled water and then dehydrated through increasing ethanol concentrations, and air-dried before hybridization. Hybridization solution [50% deionized formamide, 0.25 mg/ml yeast transfer RNA in 4ϫ SSC (20ϫ SSC in 3 M NaCl, 0.3 M sodium citrate, pH 7.0), and 5 ng digoxigenin-labeled probe/section] was applied and covered with a glass coverslip. Slides were incubated in a humidified chamber at 60°C for 16-18 h. After hybridization, coverslips were removed to 1ϫ SSC, and the sections were washed in 1ϫ SSC for 1 h at 60°C, four times for 15 min at 60°C in 1ϫ SSC, and two times in buffer 1 [150 mM NaCl and 100 mM (pH 7.5) Tris ⅐ HCl] at 25°C. Sections were then incubated in buffer 1 containing 1% BSA (Boehringer Mannheim) for 30 min at 25°C. Anti-digoxigeninhorseradish peroxidase (1.5 U/ml; Boehringer Mannheim) was added in the same buffer and incubated for 2 h. This solution was removed by aspiration, and slides were washed four times with buffer 1 at 25°C. Avidin-biotinylated-horseradish peroxidase complex (Vector Laboratories, Burlingame, CA) was added for 60 min at 25°C. Sections were washed as above and detected with 0.05% diaminobenzidine and 0.003% hydrogen peroxide in 0.1 M sodium acetate, pH 5.9, for 6 min. After being washed with distilled water and dehydrated through graded ethanols to xylenes, coverslips were mounted with Cytoseal 60 (Stephens Scientific, Kalamazoo, MI). Omission of the probe was used as a negative control.
Immunohistochemistry and electron microscopic immunocytochemistry. Human fetal tracheas from specific gestational ages were fixed in 4% buffered paraformaldehyde for 1 h, rinsed in PBS, dehydrated, and embedded in paraffin. Sections (4 m) were mounted on Superfrost plus microscope slides (Fisher). Control experiments further tested the specificity of the PQD-189 antibody to axonemal dynein and the immunolocalization procedure. This was accomplished with an immunolocalization protocol using a typically nonciliated tissue (human fetal heart at 22 wk gestation) and probing with antibodies to axonemal dynein (PQD-189) and desmin, a constitutive component of cardiac tissue. For light microscopic localization of axonemal dynein, sections of trachea at the different gestational intervals were probed with serially optimized titers of PQD-189 primary monoclonal antibody from an initial concentration of ϳ10 mg/ml and stained with Vectastain ABC reagents (Vector Laboratories) and ImmunoPure metal-enhanced 3,3Ј-diaminobenzidine substrate (Pierce) according to the manufacturer's instructions. Assay controls were performed with buffer alone in the absence of primary antibody.
For electron microscopic immunocytochemistry, fetal tracheas were fixed by immersion in 4% paraformaldehyde plus 0.25% glutaraldehyde in phosphate buffer immediately upon acquisition. The specimens were subsequently dehydrated through a graded ethanol series and embedded in Araldite. Ultrathin sections were incubated with the same primary antisera or ascites as those used for light microscopic studies, followed by washing and labeling with 10-nm colloidal goldlabeled secondary antibody. Control incubations were performed without primary antibody. The sections were poststained with lead citrate, viewed, and photographed on a Zeiss EM900 transmission electron microscope at an accelerating voltage of 50 kV.
RESULTS
Real-time RT-PCR analyses of total RNA isolated from 9-wk fetal trachea and lung suggested weak expression of DNAH9 mRNA, indicating that ciliogenesis was underway. However, ciliated cells are not observed at 9 wk in either trachea or lung, so we investigated the specificity and sensitivity of the DNAH9 mRNA TaqMan assay. We compared DNAH9 mRNA expression in undifferentiated (nonciliated) human airway epithelial cell cultures with cultures, derived from the same donor, that were undergoing mucociliary differentiation. Amplification of DNAH9 cDNA with templates from the nonciliated undifferentiated culture yielded a signal ("0" in Fig. 1A ) that was indistinguishable from the no-template background control (NT in Fig. 1A) , whereas signals well above background were observed in both the nonciliated 4-day-old differentiated culture ("4" in Fig. 1A ) and in the 12-day-old culture, which had ϳ20% ciliated cells ("12" in Fig. 1A ). The absence of signal in undifferentiated cultures was not the result Fig. 3 . Specificity of the anti-DNAH9 antibody, PQD-189. A: whole axonemes isolated from well-differentiated human airway epithelial cell cultures were left untreated (Ϫ) or subjected to V1 photolysis (ϩ) and then separated by SDS-PAGE through 3-8% gels. Duplicate gels were either silver stained (Protein) or blotted on nitrocellulose and probed with PQD-189 (IB). Although at least 5 dynein heavy chains (DHCs) were resolved (protein, square bracket) in untreated axonemes, immunoreactivity appeared as a single species (IB, arrow) that was cleaved by V1 photolysis, yielding a single immunoreactive fragment (IB, arrowhead). The immunoreactive fragment was one of a group of photolytic fragments (protein, brace) with molecular mobilities Ͼ213 kDa (213 kDa). Axonemes isolated from ϳ3 wellciliated 12-mm-diameter cultures were loaded in each well of the silver-stained and immunoblotted gels. B: schematic diagram of V1 photolysis of DHCs. V1 photolysis breaks DHCs into two fragments, a smaller amino-terminal fragment (N; Ͻ200 kDa) and a larger carboxy-terminal fragment (C; Ͼ200 kDa). The antibody epitope (PQD-189) is predicted to be on the larger fragment, in agreement with observations in A.
of scarcity of cDNA, because the level of GAPDH cDNA in the undifferentiated culture was comparable to levels in the differentiated cultures (compare 0 with 4 and 12 in Fig. 1B ). These observations were reproducible.
In five out of five differentiations of airway epithelial cells from different donors, DNAH9 mRNA was not detected in undifferentiated cultures (day 0 in Fig. 1C) , although it was detected in companion cultures undergoing mucociliary differentiation (days 4, 8, and 12, Fig. 1C ). These observations demonstrated that analysis of a complex cDNA template from undifferentiated airway epithelial cells fails to generate a specific signal in the DNAH9 mRNA TaqMan assay. In contrast to undifferentiated airway epithelial cells, analysis of the cDNA templates from 9-wk trachea and lung generated signals that were not only well above background (compare 9 vs. NT, Fig. 1, D and E) but greater than the signal generated by amplification of the lowest cDNA standard, which contained ϳ450 molecules (450, Fig. 1, D and E) . Taken together, the data strongly suggested that DNAH9 mRNA was present in the total RNAs isolated from 9-wk trachea and lung.
The kinetics of DNAH9 mRNA expression in developing trachea and lung are shown in Fig. 2 . In trachea, levels increased dramatically between 9 and 13 wk and then increased only slightly after that (compare 9, 13, 15, and 18 in Fig. 2A ). In lung, levels increased significantly between both 9 and 13 and 13 and 15 wk but were unchanged at 18 wk (compare 9, 13, 15, and 18 in Fig. 2C ). Estimates of 18S rRNA levels in templates from the trachea (Fig. 2B) and lung (Fig. 2D) showed little variation within each group, suggesting that the changes in DNAH9 mRNA are not the result of differences in the amount of total RNA input into the reverse transcription or the reverse transcription efficiency.
The relative abundance of DNAH9 mRNA at each gestational age was estimated using 18S rRNA (Fig.  2E) or GAPDH (Fig. 2F ) levels as normalization factors. Both methods of normalization yielded similar kinetics (compare Fig. 2E with Fig. 2F ). Both analyses showed that DNAH9 mRNA expression levels in trachea were approximately four (18S rRNA normalization) to ten (GAPDH normalization) times greater than levels in lung at every stage of development assayed. The increase in DNAH9 mRNA abundance was not uniform. Both trachea and lung experienced a phase of rapid expansion in DNAH9 mRNA abundance, but this phase occurred earlier in the trachea. At least 50% of the overall increase in DNAH9 mRNA abundance in the trachea occurred between 9 and 13 wk, whereas only ϳ12% of the overall increase in lung occurred. More than 80% of the overall increase in DNAH9 mRNA abundance in lung occurred between 13 and 15 wk. These observations suggested that, although ciliated cell differentiation was underway at 9 wk in trachea and lung, differentiation in the trachea was accelerated with respect to lung. DNAH9 protein has been characterized previously by immunoblotting of bronchial cell ciliary axonemes using PQD-189, a monoclonal antibody raised to a fragment of the deduced amino acid sequence of DNAH9 (36) . In those studies, PQD-189 staining was restricted to proteins of very high molecular weight. However, there are a number of DHCs with similar molecular weights that migrate in the region stained by PDQ-189. Consequently, the specificity of PQD-189 was investigated by additional immunoblotting of axonemal proteins separated by extended SDS-PAGE. Although at least five distinct DHCs were resolved in axonemes, only a single immunoreactive species was observed (Fig. 3A) . The possibility that two or more DHCs recognized by PQD-189 were comigrating was investigated in further detail by immunoblotting of axonemes subjected to V1 photolysis. Irradiation of axonemes with ultraviolet light in the presence of ATP and metavanadate split the DHCs, yielding smaller DHC fragments that are more easily resolved from one another (Fig. 3A) . Only a single V1 photolysis product was immunoreactive (Fig. 3A) . These data supported the notion that PDQ-189 is specific for a single DHC.
The results of in situ hybridization histochemistry (Fig. 4) were complementary to the quantitative PCR data. At 9-11 wk gestation (late 1st trimester), axonemal dynein expression was not evident in the tracheal epithelium (Fig. 4A) . However, time points in the second trimester (Fig. 5, B and C) showed prominent and progressive expression. At 22 wk gestation, when epithelial growth and differentiation approach maturity, in situ hybridization again showed a decline in the intensity of localization.
Tests of the specificity of the PQD-189 antibody to axonemal dynein for immunolocalization have been reported previously (36) and were documented again in this study by the absence of localization in fetal heart, a typically nonciliated tissue. A procedural control showed positive localization of desmin, a constitutive component of cardiac tissue in the same specimen (Fig.  5, A and B) .
Light microscopic examination of human fetal tracheal epithelium at different gestational ages (Fig. 6 , A, C, and E) revealed organization and developmental patterns consistent with other reports in the literature (8, 10, 11, 26, 27) . At the earliest stage examined, nine gestational weeks (Fig. 6A) , there was no evidence of cilia at the light microscopic level. Progressive ciliation was observed in the second trimester (Fig. 6, C  and E) , and by 22 gestational weeks the epithelial layer was fully ciliated and developed and indistinguishable from normal adult airway epithelium (Fig. 6G) .
In an effort to identify nascent ciliated cells in the developing trachea and lung, we localized DNAH9 protein by light and electron microscopic immunocytochemistry. PQD-189 immunoreactivity in human fetal tissues was observed as early as 10 wk gestation as a dark band of the chromogen along the luminal border of some epithelial cells (Fig. 6B) . As epithelial maturation progressed, both the cytoplasm and emergent ciliary beds exhibited marked localization in the epithelial cell cytoplasm (Fig. 6, D and F) . In contrast, normal human adult bronchial epithelium exhibited marked immunostaining of ciliary beds by PQD-189 (Fig. 6H) , but, unlike fetal tissues, no localization was observed in the cytoplasm of adult tracheal epithelial cells. Electron microscopic immunocytochemistry was used in an attempt to more specifically localize the axonemal dynein antigen to the nascent ciliating cells that exhibit limited morphological evidence of ciliary structure and ciliogenesis at the light microscopic level. Electron microscopic immunocytochemistry of human fetal tracheal epithelium revealed cytoplasmic localization of the antigen by the PQD-189 monoclonal antibody to human axonemal dynein in the apical cytoplasm of human fetal tracheal epithelium at 10 gestational weeks (Fig. 7A) . Localization of colloidal gold particles Fig. 5 . Tests of the specificity of the PQD-189 antibody and the immunolocalization protocol were performed by immunostaining 22-wk human fetal heart with antibody to desmin as a positive control (A) and axonemal dynein (PQD-189 antibody; B) . No localization of axonemal dynein was evident inasmuch as cardiac tissue was not ciliated. was more extensive in epithelial cell cytoplasm and ciliary axonemes of tissues obtained at later intervals, and, as epithelial maturation and ciliated cell differentiation proceeded, amorphous aggregates of gold localization were more evident in the apical cytoplasm (Fig.  8A ). More organized linear arrays of gold particles were evident in close proximity to luminal membranes (Fig. 8C ) and in cytoplasmic sites containing evident Fig. 6 . Light microscopic assessment of ciliation in human fetal and adult large airway epithelium (A, C, E, and G). At 9 wk gestation [A; hematoxylin and eosin (H&E) stain], no cilia were visible by light microscopy. By 15 wk gestation (C; H&E stain), intermittent beds of cilia could be identified on the luminal border. At 22 wk gestation (E; H&E stain), the superficial epithelial border was fully ciliated and comparable in organization to normal adult large airway epithelium (G). Micrograph of adult airway epithelium (G) also represents a control to the immunocytochemical localization studies (B, D, F, and H). It was processed without histological staining and without incubation in the primary PQD-189 monoclonal antibody and was photographed by Nomarski differential interference contrast to highlight the ciliary beds. At 10 gestational weeks (B), the absence of cilia was evident in the immunocytochemical preparations; however, localization of the axonemal dynein antigen (arrow) can be seen along the luminal border of one cell, providing evidence of early axonemal dynein expression at a cellular site consistent with ciliogenic activity. At 17 and 22 wk gestation (D and F), cilia were clearly labeled, as was the cytoplasm of the ciliated epithelial cells. Although the cilia containing axonemal dynein were clearly labeled in a biopsy of adult human airway epithelium (H), the cytoplasm lacked evidence of localization. axonemal structures (Fig. 8, B and D) at later gestational ages.
DISCUSSION
We have applied molecular and morphological approaches to clarify the temporal aspects of expression of a functionally critical and distinctive component of ciliated cells, axonemal dynein, early in human fetal airway development. Our observations indicate that an RNA encoding an axonemal DHC, DNAH9, is detectable as early as 9 wk gestation in human fetal lung and trachea. Furthermore, DNAH9 protein is detectable by 10 gestational weeks in the airway epithelium by immunocytochemical localization at the light and electron microscopic levels. These observations suggest that axonemal dynein gene expression may be underway for 2-3 wk before there is morphological evidence of ciliary axonemes in the fetal airway epithelium.
The kinetics of DNAH9 mRNA relative abundance in developing human trachea and lung that were obtained in this study appear to be valid, on the basis of the following correlations. First, the relative abundance of DNAH9 mRNA was ϳ4-10 times higher in the trachea (Fig. 2, E and F) , in keeping with the greater abundance of ciliated cells in the trachea relative to the lung, in which only the airways are ciliated. Second, the rate of increase in DNAH9 mRNA relative abundance was highest between 9 and 13 wk in the trachea, whereas it was greatest between 13 and 15 wk in lung (Fig. 2, E and F) . Although other explanations may be possible, the data are consistent with the proximal-to-distal progression of airway maturation.
The specificity of the anti-DNAH9 antibody, PQD-189, was supported by immunoblotting of human axonemes. It was already known that PQD-189 reacts selectively with one or more very high molecular weight proteins present in human axonemes (36) . However, the high sequence similarity and similar molecular weights of DHCs make cross-reactivity with PQD-189 a possibility that had not been ruled out. Crossreactivity of PQD-189 with human DHCs was investigated by extended one-dimensional SDS-PAGE of axonemes before and after V1 photolysis. Five distinct DHCs were resolved in axonemes (Fig. 3A) . Al- though the number of distinct DHCs present in the axoneme is still uncertain, there are undoubtedly more than five. Enumeration of DHCs in Chlamydomonas suggests that there are at least 14 DHCs that are structural components of its axoneme (33) . V1 photolysis of DHCs was used to yield smaller fragments of DHCs that are more likely to be separated (2) . The presence of a single immunoreactive species under all conditions suggested that PQD-189 recognizes a single axonemal DHC. Moreover, the data supported the notion that PQD-189 recognizes a human DHC because sensitivity to V1 photolysis is a characteristic of DHCs (15) and confirmed the predicted presence of the epitope recognized by the antibody on the larger carboxy-terminal V1 photolysis fragment of the DHC (shown in Fig. 3B ).
Previous studies (8, 10, 11, 26, 27) have documented that ciliation of the human fetal tracheal epithelium occurs from approximately 11 to 20 wk gestation. Before this time, the tracheal epithelium is an undifferentiated columnar epithelium. In the present study, immunohistochemical studies localized the PQD-189 antibody to the luminal borders of nascent ciliating cells before 12 wk gestation, when ciliary beds can be identified by morphological criteria. Once cilia emerged along the luminal borders of the epithelium, PQD-189 clearly localized on the axonemal shafts. Furthermore, the antibody localized to the cytoplasm and cilia in the second trimester, whereas in the bronchial epithelium of a healthy adult human subject, PQD-189 localized only to cilia, suggesting that cytoplasmic localization of axonemal dynein, evidenced by immunostaining with PQD-189 antibody, may be more readily detectable in nascent ciliating cells actively undergoing ciliogenesis. This observation also is consistent with the in situ hybridization studies suggesting that axonemal dynein expression declines as the epithelium approaches maturity.
Previous histological and ultrastructural studies (4, 21) have suggested that turnover of the epithelium in the lower airways is attenuated relative to the nasal epithelium, where environmental irritants and a resident microbial flora may contribute to more rapid turnover. This notion is supported by the observation that ciliogenic profiles in the lower airway epithelium of healthy individuals are rarely observed, whereas such profiles in the nasal epithelium are common. Our comparative immunohistochemical observations of human fetal and adult airway epithelium also suggest that detection of axonemal dynein expression and immunohistochemical localization of antigen appear to be associated with phases of rapid growth and differentiation that subsequently decline with epithelial maturation.
In summary, our observations suggest that axonemal dynein expression occurs as an early event in the differentiation of the ciliated cell component of the developing human airway epithelium and precedes more overt morphological manifestations of ciliogenesis. These studies have further reinforced the specificity of the PQD-189 antibody to human axonemal dynein and suggest its utility as a means of identifying cells in early stages of ciliated cell differentiation. This capability may be useful for future investigations of epithelial remodeling and phenotypic transition that may be associated with acute and chronic respiratory disease processes. Inasmuch as emerging gene-therapeutic technologies may require targeting of specific cell types, this antibody may also find utility as a marker of early ciliated cell differentiation.
